Overcoming Immune Resistance in Bladder Cancer: From ExhaustedT-Cells and Microbiome Crosstalk to Next-Generation CombinationTherapies

Bladder cancer remains a formidable malignancy of the urinary system, with treatment significantly challenged by the frequent development of resistance to Immune Checkpoint Inhibitors (ICIs). The review is an in-depth and methodical account of the several causes of this immune resistance, and reviews new ways of reversing it. We suggest a unified model based on three fundamental dimensions: (1) characterized by T-cell exhaustion, with high expression of co-inhibitory receptors such as TIM-3 and LAG-3 that SELLs the anticancer immune function and limits efficacy of PD-1/PD-L1 blockade; (2) systemic regulation of immunity through the gut-bladder axis in which microbiota, particularly commensals like Akkermansia muciniphila, regulate host immune responses and affect immunotherapy results; and (3) adaptive tumor evolution caused by an immunosuppressive Tumor Microenvironment (TME), along with genetic changes to help escape immune destruction. The interaction between these factors highlights the intricacy of treatment resistance. This limitation can be successfully overcome through rationalized combination therapies. We revisit changing strategies, including ICI plus Antibody Drug Conjugates (ADC), enfortumab vedotin. These ADCs have the ability to destroy tumor cells selectively and kill the tumor simultaneously through the induction of immunogenic cell death, which has the potential to alter TME, promote T-cell infiltration, and demonstrate synergistic effects with ICIs. However, other promising techniques are the simultaneous interference with TIM3/LAG3 or microbiome manipulation. By combining general knowledge with recent clinical information, this review also gives an ordered perspective of immune resistance and assists in the creation of multi-target treatments. In general, these developments have potential for improved patient care and long-term survival in advanced bladder cancer